ROLE OF MILK IN COGNITIVE FUNCTION AND QUALITY OF LIFE IN OLDER ADULTS WITH MILD COGNITIVE IMPAIRMENT A1 protein free milk may provide enhanced outcomes
With
Dr Emma Beckett,
Food & Nutrition Scientist, FOODiQ Global
Professor Stephen Robinson, Psychology Research
Researcher and corresponding author &
semi-retired neuroscientist, RMIT University
AUSTRALIAN HEALTH JOURNAL SEGMENT
Filmed in Melbourne and Newcastle, NSW | September 2025
New research emphasises the role of cows’ milk, particularly A1 protein free milk, in enhancing cognitive function and quality of life for older adults with mild cognitive impairment (MCI). A multi-centre, double-blinded, randomised controlled clinical study published in *The Journal of Nutrition, Health and Aging* evaluated 88 milk-tolerant Chinese adults aged 65-75 over three months. Participants consumed either ordinary skim milk or A1 protein free skim milk, leading to improvements in various cognitive assessments.
Both types of milk showed significant enhancements in cognitive performance across multiple tests, including the Subtle Cognitive Impairment Test (SCIT), Montreal Cognitive Assessment (MoCA), and Audio Verbal Learning Test (AVLT).
While both groups reported improvements in quality of life, the A1 protein free group noted greater gains, including a 23% increase in overall quality of life scores and a 43% improvement in memory ability. Despite challenges with vitamin D levels among participants, the study highlights the importance of milk choice in promoting cognitive health, especially for the aging population, where approximately 20% of those over 65 may experience MCI.
Researcher and corresponding author of the clinical study, Professor Stephen Robinson spoke to Australian Health Journal about the findings and the need for further research to confirm these benefits across diverse populations.
Dr Emma Beckett, food and nutrition scientist at FOODiQ, says A1PF milk, as part of a balanced diet, can play a valuable role in improving the nutrition of older adults.
“This is an exciting study because it shows that a small dietary change, adding A1PF milk, may be effective for those experiencing cognitive changes. As Australia’s population continues to age, A1PF milk may offer an accessible way to support overall health and wellbeing, particularly in adults living with MCI,” said Dr Beckett.
Source: Adapted from a2 Milk Australia media release and published study
-
Delivering anaesthetic services to countries where surgical services can’t be provided
Dr Wendy Falloon is an Anaesthetist of over 30 years experience and a Fellow of Australian and New Zealand College of Anaesthetists (ANZCA). She studied medicine at the University of Tasmania, and worked in Hobart, Sydney and the Uk while completing her specialist qualifications. Her primary professional focus has always been to deliver the best possible experience of anaesthesia to each and every patient, and for them to know that she sees and values them, and their stories.
Having been born in Africa, she realised even as a child that health and wealth were largely a product of where people happen to be born. This sowed the seed of her ongoing desire to be of help to others in less fortunate circumstances, ultimately leading to her volunteer work with the Mercy Ships charity. This is one of the most fulfilling aspects of her career, and she has volunteered in Africa with Mercy Ships 8 times since 2014.
-
Imperatives for women diagnosed with ovarian cancer
Professor Clare Scott, a pioneering clinician scientist at the Walter and Eliza Hall Institute of Medical Research in Melbourne, also serves as a medical oncologist at Peter MacCallum Cancer Centre, the Royal Melbourne Hospital, and the Royal Women’s Hospital.
Her comprehensive training in medical oncology has fuelled her specialisation in gynaecological cancer, combining rigorous research with clinical trials to improve patient outcomes. With over a decade of involvement in ANZGOG, Australia’s foremost gynaecologic cancer research organisation, she is deeply committed to advancing research and saving lives.
-
World-first clinical trial improves patient outcomes for kidney transplants
A world-first clinical trial conducted at the Royal Adelaide Hospital (RAH) and at hospitals across Australia and New Zealand has identified the best fluid treatment to reduce the risk of patients requiring dialysis after a kidney transplant.
Australian Health Journal spoke with the lead-author of the study, RAH Nephrologist and University of Adelaide researcher, Dr Michael Collins.
